MedTrace Logo

The Effect Of AVANDIA On The Late Asthmatic Response

NCT00318630 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-09-25

No results posted yet for this study

Summary

This study is to investigate the effects of AVANDIA on the asthmatic response.

Conditions

Interventions

DRUG

Rosiglitazone

Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.

DRUG

Placebo

Subjects will also receive placebo oral tablet.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-22
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00318630 on ClinicalTrials.gov